<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02263495</url>
  </required_header>
  <id_info>
    <org_study_id>2014-0857</org_study_id>
    <nct_id>NCT02263495</nct_id>
  </id_info>
  <brief_title>Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer</brief_title>
  <acronym>EG_PG</acronym>
  <official_title>A Phase II, Multicenter, Randomized Trial of Eribulin Plus Gemcitabine (EG) vs.Paclitaxel Plus Gemcitabine (PG) in Patients With HER2-Negative Metastatic Breast Cancer as First -Line Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Samyang Biopharmaceuticals Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Metastatic breast cancer (MBC) is an incurable disease and is needed to improve effective&#xD;
      chemotherapy. Paclitaxel plus Gemcitabine (PG) combination chemotherapy is one of the&#xD;
      preferred chemotherapeutic regimens for patients with MBC, and was found to be proper as a&#xD;
      maintenance chemotherapy regimen with survival benefit and feasible toxicity profile as shown&#xD;
      in a large phase III KCSG (Korean Cancer Study Group) study (Park Y et al. J Clin Oncol&#xD;
      31(14):1732, 2013).&#xD;
&#xD;
      Eribulin mesylate is a microtubule-targeting agent that showed improved overall survival&#xD;
      benefit as monotherapy for MBC patients as a new chemotherapeutic agent after failure of&#xD;
      anthracycline and taxane in EMBRACE study (Cortes J et. al. Lancet 377:914-923, 2011).&#xD;
      Eribulin was also reported its promising efficacy in another randomized phase III study that&#xD;
      demonstrated eribulin as efficacious as capecitabine (Kaufman P et. al. Abstr# S6-6, SABCS&#xD;
      2012). Both study results showed potential clinical benefit in patients with triple negative&#xD;
      MBC (TNBC). Thus, eribulin combined with gemcitabine may be a new potential regimen for early&#xD;
      line therapy in patients with metastatic breast cancer.&#xD;
&#xD;
      Furthermore, eribulin may have rational benefit compared with paclitaxel in terms of&#xD;
      neurotoxicity. Although there is no direct evidence that eribulin has better neurotoxicity&#xD;
      profile than taxane, eribulin tended to show less neurotoxicity compared with ixabepilone in&#xD;
      a phase II trial (Vahdat, L et al. 2011 SABCS). Eribulin has no worsen toxicity as compared&#xD;
      to paclitaxel. Therefore, EG may have less neurotoxicity comparing to PG.&#xD;
&#xD;
      In phase I trial, eribulin in combination with gemcitabine was feasible in patients with&#xD;
      advanced solid tumor treated with chemotherapy (&lt; 3 lines) (Goel R, et al, 2009 ASCO).&#xD;
&#xD;
      Based on this rationale, the investigators are to conduct randomized phase II study comparing&#xD;
      EG chemotherapy with PG chemotherapy for patients with HER-2 negative MBC as first-line&#xD;
      chemotherapy.&#xD;
&#xD;
      A total of 118 patients will be recruited. Patients will be randomized to a treatment arm by&#xD;
      permutated method. The randomization ratio is 1:1. This study is multi-center, randomized,&#xD;
      open label study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of enrolled 118 patients in EG and PG groups, will be provided chemotherapy regimen:&#xD;
&#xD;
      Paclitaxel/Gemcitabine (PG) : every 3 weeks D1 Paclitaxel 175mg/m2 + D5W 500mL MIV over 3hrs&#xD;
      before gemcitabine administration D1, D8 Gemcitabine 1,250 mg/m2 + NormalSaline 100ml MIV&#xD;
      over 30mins&#xD;
&#xD;
        -  Pre &amp; Post medication (which can be changed according to institutions' policy) D1&#xD;
           Corticosteroid 100 mg i.v. 30 min. before Paclitaxel Pheniramine 1A + D5W 50mL MIV&#xD;
           30mins before Paclitaxel Ranitidine 50mg IV + D5W 50mL MIV 30mins before Paclitaxel HT3&#xD;
           antagonist 1A + D5W 50 mL MIV 30mins before Paclitaxel&#xD;
&#xD;
      Eribulin/Gemcitabine (EG): every 3weeks D1, D8 Eribulin 1.0 mg/m2, 2-5min iv before&#xD;
      gemcitabine (or miv with NormalSaline 100ml in max.) D1, D8 Gemcitabine 1000 mg/m2 +&#xD;
      NormalSaline100ml MIV over 30mins&#xD;
&#xD;
      &lt;schedule of Assessment adn procedures (±3 days window period ) &gt;&#xD;
&#xD;
        1. screening /baseline&#xD;
&#xD;
             -  obtaining Informed consent form&#xD;
&#xD;
             -  collecting information&#xD;
&#xD;
             -  demographic data&#xD;
&#xD;
             -  breast cancer treatment history/ medical history&#xD;
&#xD;
             -  general physical examination/ vital sign &amp; Performance status&#xD;
&#xD;
             -  Test: CBC/blood chemistry/ Tumor response(CT or MRI)/&#xD;
&#xD;
             -  collecting QOL questionnaire using FACT-Taxane&#xD;
&#xD;
        2. cycle 1 ~ prior to EOT&#xD;
&#xD;
             -  general physical examination/ vital sign &amp; Performance status&#xD;
&#xD;
             -  Test: CBC/blood chemistry/ Tumor response(CT or MRI)&#xD;
&#xD;
             -  collecting QOL questionnaire using FACT-Taxane&#xD;
&#xD;
             -  administration PG or EG&#xD;
&#xD;
        3. EOT(end of treatment)&#xD;
&#xD;
             -  general physical examination/ vital sign &amp; Performance status&#xD;
&#xD;
             -  Test: CBC/blood chemistry/ Tumor response(CT or MRI)&#xD;
&#xD;
             -  collecting QOL questionnaire using FACT-Taxane&#xD;
&#xD;
        4. survival follow up(every 12weeks)&#xD;
&#xD;
             -  survival&#xD;
&#xD;
             -  anti neoplastic therapy after end of treatment&#xD;
&#xD;
             -  The tumor response will be performed every 12 (±2) weeks until disease progression&#xD;
&#xD;
      &lt;WITHDRAWAL OF SUBJECTS&gt;&#xD;
&#xD;
      Subjects may be withdrawn from the study (i.e. from any further study medication or study&#xD;
      procedure) for the following reasons:&#xD;
&#xD;
        -  At their own request&#xD;
&#xD;
        -  If, in the investigator's opinion, continuation in the study would be detrimental to the&#xD;
           subject's well-being&#xD;
&#xD;
        -  In case of disease progression&#xD;
&#xD;
        -  In case of unacceptable toxicity&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 19, 2014</start_date>
  <completion_date type="Actual">June 17, 2019</completion_date>
  <primary_completion_date type="Actual">May 11, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>48months</time_frame>
    <description>To demonstrate that EG is not inferior to PG group in terms of PFS in patients with metastatic or recurrent breast cancer as first-line treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>48months</time_frame>
    <description>Survival will be measured as the time from randomization to the date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neuropathic scale</measure>
    <time_frame>expected at 9week , expected at 24week</time_frame>
    <description>FACT for Taxane QOL assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity of study drugs</measure>
    <time_frame>from first administration until 28 days after the last dose administration</time_frame>
    <description>Using CTCAE Version 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response</measure>
    <time_frame>48months</time_frame>
    <description>using RECIEST version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>48months</time_frame>
    <description>using RECIEST version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical benefit rate</measure>
    <time_frame>48months</time_frame>
    <description>using RECIEST version 1.1</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Paclitaxel &amp; Gemcitabine(PG)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel 175mg/m2 IV , Day1,every 3weeks Gemcitabine 1250mg/m2 IV ,Day1&amp; Day8 every 3weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eribulin &amp; Gemcitabine(EG)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eribulin 1.0 mg/m2, 2-5min iv ,Day1&amp; Day8 every 3weeks Gemcitabine 1,000 mg/m2 ,Day1&amp; Day8 every 3weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>175mg/m2 + D5W 500mL MIV over 3hrs before gemcitabine administration</description>
    <arm_group_label>Paclitaxel &amp; Gemcitabine(PG)</arm_group_label>
    <other_name>Genexol,</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eribulin</intervention_name>
    <description>1.0 mg/m2, 2-5min iv before gemcitabine (or miv with NS 100ml in max.)</description>
    <arm_group_label>Eribulin &amp; Gemcitabine(EG)</arm_group_label>
    <other_name>Halaven,</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>PG:1250mg/m2 + NS 100ml MIV over 30mins EG:1000mg/m2 + NS 100ml MIV over 30mins</description>
    <arm_group_label>Eribulin &amp; Gemcitabine(EG)</arm_group_label>
    <arm_group_label>Paclitaxel &amp; Gemcitabine(PG)</arm_group_label>
    <other_name>Gemcit</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed metastatic, or recurrent breast cancer&#xD;
&#xD;
          2. HER2-negative breast cancer&#xD;
&#xD;
          3. age &gt; 18 years&#xD;
&#xD;
          4. ECOG performance status 0 - 2&#xD;
&#xD;
          5. Pre- or postmenopausal breast cancer patients with measurable or non-measurable&#xD;
             lesions, who are candidates for chemotherapy&#xD;
&#xD;
          6. Life expectancy ≥ 3 months&#xD;
&#xD;
          7. No prior history of chemotherapy for metastatic, recurrent breast cancer&#xD;
&#xD;
          8. Patients may have received prior neoadjuvant or adjuvant taxane regimen as long as it&#xD;
             has been 12 months since completion of regimen.&#xD;
&#xD;
          9. Patients either may or may not have a prior anthracycline containing regimen.&#xD;
&#xD;
         10. Prior hormonal therapy as a treatment of metastatic disease is allowed. But&#xD;
             antitumoral hormonal therapy must be terminated prior to enrollment(up to the date of&#xD;
             randomization)&#xD;
&#xD;
         11. Prior radiation therapy allowed as long as &lt; 25% of the bone marrow has been treated,&#xD;
             and the patients must have recovered from the acute toxic effects of the treatment&#xD;
             prior to study enrollment. Prior radiation to the whole pelvis is not allowed. Prior&#xD;
             radiotherapy must be completed 2 weeks before study entry.&#xD;
&#xD;
         12. Bisphosphonates for the treatment of bone metastases should not be initiated following&#xD;
             the first dose of randomized therapy. It must be initiated prior to day of treatment&#xD;
             (cycle 1, day 1). Patients may continue on bisphosphonates who already established on&#xD;
             bisphosphonate therapy for bone metastases&#xD;
&#xD;
         13. Adequate bone marrow function (≥ ANC 1,500/ul, ≥ platelet 100,000/ul, ≥ Hemoglobin 9.0&#xD;
             g/dl)&#xD;
&#xD;
         14. Adequate renal function (≤ serum creatinine 1.5 mg/dl or CCr ≥ 50 ml/min)&#xD;
&#xD;
         15. Adequate liver function (≤ serum bilirubin 1.5 mg/dl, ≤ AST &amp; ALTX3 upper normal limit&#xD;
             or AST and ALT ≤ 5.0XULN if judged by the investigator to be related to liver&#xD;
             metastases)&#xD;
&#xD;
         16. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Serious uncontrolled intercurrent infections&#xD;
&#xD;
          2. Serious intercurrent medical or psychiatric illness, including active cardiac disease&#xD;
&#xD;
          3. Pregnancy or breast feeding&#xD;
&#xD;
          4. Second primary malignancy(except in situ carcinoma of the cervix or adequately treated&#xD;
             nonmelanomatous carcinoma of the skin or other malignancy treated at least 5 years&#xD;
             previously with no evidence of recurrence)&#xD;
&#xD;
          5. Documented parenchymal or leptomeningeal brain metastasis&#xD;
&#xD;
          6. Peripheral neuropathy ≥ grade 2&#xD;
&#xD;
          7. Prior treatment with gemcitabine will not be allowed.&#xD;
&#xD;
          8. HER-2 overexpressing breast cancer and concomitant trastuzumab treatment is not&#xD;
             allowed&#xD;
&#xD;
          9. Women of childbearing potential, unwilling to use a medically acceptable method of&#xD;
             contraception during the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung Hae Jung, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 6, 2014</study_first_submitted>
  <study_first_submitted_qc>October 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2014</study_first_posted>
  <last_update_submitted>July 12, 2020</last_update_submitted>
  <last_update_submitted_qc>July 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Kyung Hae Jung</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>HER2-Negative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

